Two Sigma Investments LP Trims Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Two Sigma Investments LP lessened its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 44.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 126,446 shares of the company's stock after selling 101,027 shares during the period. Two Sigma Investments LP owned 0.26% of Mirum Pharmaceuticals worth $5,229,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Summit Investment Advisors Inc. lifted its position in shares of Mirum Pharmaceuticals by 8.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock worth $172,000 after acquiring an additional 312 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after purchasing an additional 357 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in Mirum Pharmaceuticals by 2.9% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 17,200 shares of the company's stock worth $711,000 after purchasing an additional 487 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Mirum Pharmaceuticals in the 4th quarter worth about $35,000. Finally, Legato Capital Management LLC grew its holdings in Mirum Pharmaceuticals by 7.9% during the 4th quarter. Legato Capital Management LLC now owns 13,395 shares of the company's stock valued at $554,000 after buying an additional 977 shares in the last quarter.

Mirum Pharmaceuticals Trading Up 0.8%

Shares of NASDAQ:MIRM traded up $0.34 on Friday, reaching $44.34. 336,375 shares of the company traded hands, compared to its average volume of 519,724. The stock has a market capitalization of $2.20 billion, a P/E ratio of -21.95 and a beta of 0.95. The business's 50-day simple moving average is $42.62 and its 200 day simple moving average is $44.67. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.99 and a 52 week high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. The business had revenue of $111.59 million for the quarter, compared to analyst estimates of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. Mirum Pharmaceuticals's revenue for the quarter was up 61.2% compared to the same quarter last year. During the same period last year, the company earned ($0.54) EPS. As a group, equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 27,279 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the completion of the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at approximately $6,129,318.61. This represents a 16.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Peter Radovich sold 7,879 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $348,330.59. Following the completion of the sale, the chief operating officer now directly owns 18,672 shares in the company, valued at approximately $825,489.12. The trade was a 29.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 92,764 shares of company stock valued at $4,109,161 in the last quarter. Company insiders own 14.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MIRM. HC Wainwright restated a "buy" rating and issued a $73.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. JMP Securities raised their target price on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a research note on Friday, May 9th. Robert W. Baird boosted their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research note on Thursday, February 27th. Finally, Raymond James reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. Ten research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $60.73.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.